This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David N. Mohr, MD; Kenneth P. Offord, MS; L. Joseph Melton III, MD
Mayo Clinic and Mayo Foundation Rochester, Minn

JAMA. 1986;256(19):2674-2675.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

One of the difficulties in ascertaining the ability of asymptomatic microhematuria to predict the existence of renal or uroepithelial cancer is that the gold standard of diagnosis, excretory urography and cystoscopy, entails risks. The ethics of studies in man would generally preclude performances of these tests on all asymptomatic adults with one or more red blood cells per high-power field on urinalyses. However, the results of such tests on a high-risk subgroup, such as patients whom physicians have referred to urologists, cannot be applied to the general population. Thus, one must study a defined general population by observing the appearance of disease after an abnormal urinalysis result. Dr Heller must have overlooked our reporting on page 227 of patients who had urologic tests in the month after their urinalysis, but this does not resolve his legitimate concern that hematuria may be a clue to the preclinical phase of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?